Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

“The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine,” stated Lisa Ricciardi, Cognition’s president and CEO. “The alignment we achieved with the FDA on a registrational path in Alzheimer’s disease was an important accomplishment. We were encouraged by the agency’s receptivity to study designs and recruitment strategies that support faster, more cost-effective studies. Looking ahead, we believe the clinical pharmacology and bioavailability studies we are conducting will support all planned registrational programs for zervimesine.”